1. Home
  2. CYTH

as 12-20-2024 4:00pm EST

$
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.

Founded: 1990 Country:
United States
United States
Employees: N/A City: GAINESVILLE
Market Cap: 20.4M IPO Year: N/A
Target Price: $0.95 AVG Volume (30 days): 43.6K
Analyst Decision: Buy Number of Analysts: 3
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.92 EPS Growth: N/A
52 Week Low/High: $0.57 - $2.12 Next Earning Date: 11-14-2024
Revenue: $870,725 Revenue Growth: -8.52%
Revenue Growth (this year): -8.43% Revenue Growth (next year): 24.49%

CYTH Daily Stock ML Predictions

Share on Social Networks: